Trophogen has a unique and very broad platform technology to develop patented long-acting, much more potent & effective, and totally safe non-immunogenic human and animal superagonist analogs of glycoprotein hormones and growth factors. The company is seeking investments to address multi-billion dollar markets in infertility, elective egg banking, and untreatable & aggressive cancers. The first 3 human products of this very broad platform, FSH, TSH, and VEGF superagonist analogs plus Nanotechnology, are fully developed and ready for IND and Clinical Trials. Trophogen’s BioSuperior platform technologies will supercede all current BioBetters, BioSimilars, and current market drugs in their respective imaging, diagnostic and therapeutic space.